Published in J Androl on April 06, 1993
The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A (2002) 5.98
Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A (1998) 1.74
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Behavioral stress accelerates prostate cancer development in mice. J Clin Invest (2013) 1.52
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A (1993) 1.29
Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol (1995) 1.24
Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis. J Physiol (2000) 1.08
Androgen responsive intronic non-coding RNAs. BMC Biol (2007) 1.07
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. Am J Pathol (2004) 0.99
Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest (2003) 0.93
BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells. PLoS One (2013) 0.86
Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol (2010) 0.85
Gene targeting to the stroma of the prostate and bone. Differentiation (2008) 0.84
Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells. Neoplasia (2003) 0.83
Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect (1999) 0.83
Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art. Cancer Manag Res (2010) 0.81
Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int (2011) 0.81
Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients? Contemp Oncol (Pozn) (2015) 0.78
Molecular targets for radiation oncology in prostate cancer. Front Oncol (2011) 0.78
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77
Stem cells in genetically-engineered mouse models of prostate cancer. Endocr Relat Cancer (2015) 0.77
Surgical stress delays prostate involution in mice. PLoS One (2013) 0.76
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathol Oncol Res (1996) 0.76
Anticancer Effect of Fucoidan on DU-145 Prostate Cancer Cells through Inhibition of PI3K/Akt and MAPK Pathway Expression. Mar Drugs (2016) 0.75
Proliferative, structural and molecular features of the Mdx mouse prostate. Int J Exp Pathol (2010) 0.75
Pathways between socioeconomic determinants of health. J Epidemiol Community Health (2004) 2.54
Predictors of early retirement in British civil servants. Age Ageing (2000) 2.45
Socioeconomic inequalities in mortality among women and among men: an international study. Am J Public Health (1999) 2.31
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Is retirement good or bad for mental and physical health functioning? Whitehall II longitudinal study of civil servants. J Epidemiol Community Health (2003) 1.98
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Do risk factors and health behaviours contribute to self-ratings of health? Soc Sci Med (1999) 1.93
Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. Eur Urol (2002) 1.91
Examining the continuity of self-rated health. Int J Epidemiol (1998) 1.83
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res (1990) 1.82
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
Occupational class and ischemic heart disease mortality in the United States and 11 European countries. Am J Public Health (1999) 1.68
Socioeconomic inequalities in diabetes mellitus across Europe at the beginning of the 21st century. Diabetologia (2008) 1.66
Job insecurity in white-collar workers: toward an explanation of associations with health. J Occup Health Psychol (2001) 1.65
Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proc Natl Acad Sci U S A (1991) 1.63
Massive multicystic dilatation of the uterine wall with myometrial venous thrombosis during pregnancy. Ultrasound Obstet Gynecol (2004) 1.45
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
Self-reported economic difficulties and coronary events in men: evidence from the Whitehall II study. Int J Epidemiol (2005) 1.43
Employment status and health after privatisation in white collar civil servants: prospective cohort study. BMJ (2001) 1.42
Socio-economic inequalities in mortality. Methodological problems illustrated with three examples from Europe. Rev Epidemiol Sante Publique (1998) 1.37
Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res (2001) 1.35
Understanding income inequalities in health among men and women in Britain and Finland. Int J Health Serv (2000) 1.31
Cumulative social class and mortality from various causes of adult men. J Epidemiol Community Health (2003) 1.30
Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol (1996) 1.30
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A (1993) 1.29
bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology (1998) 1.29
Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene (1993) 1.29
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer (2003) 1.25
Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. Prostate (1985) 1.25
Neighbourhood unemployment and all cause mortality: a comparison of six countries. J Epidemiol Community Health (2005) 1.25
Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res (2000) 1.23
Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate (1988) 1.22
Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ (1998) 1.22
Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res (2001) 1.22
Educational differences in cancer mortality among women and men: a gender pattern that differs across Europe. Br J Cancer (2008) 1.21
Education, survival and avoidable deaths in cancer patients in Finland. Br J Cancer (2010) 1.21
Gender differences in illhealth in Finland: patterns, magnitude and change. Soc Sci Med (1999) 1.21
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res (1999) 1.18
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. J Urol (1997) 1.13
Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res (1991) 1.12
Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer (1996) 1.12
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate (1989) 1.11
The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol (1994) 1.09
Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology (1990) 1.07
Health-related behaviours and sickness absence from work. Occup Environ Med (2009) 1.06
Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer (1997) 1.04
Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch (2005) 1.04
Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol (1999) 1.04
Ultrastructural differences in efferent ducts and several regions of the epididymis of the hamster. Am J Anat (1978) 1.01
Explanations for gender differences in sickness absence: evidence from middle-aged municipal employees from Finland. Occup Environ Med (2008) 1.00
Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol (2003) 1.00
Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis (2002) 0.99
Time trends in mortality in forestry and construction workers in Finland 1970-85 and impact of adjustment for socioeconomic variables. J Epidemiol Community Health (1993) 0.99
Explaining occupational class differences in sickness absence: results from middle-aged municipal employees. J Epidemiol Community Health (2009) 0.98
Gender differences in the relationship of partner's social class to behavioural risk factors and social support in the Whitehall II study. Soc Sci Med (2004) 0.98
Psychosocial working conditions and weight gain among employees. Int J Obes (Lond) (2005) 0.97
Isolation of potentially pathogenic mycobacteria in the Finnish environment. Scand J Infect Dis Suppl (1995) 0.97
Home ownership and mortality: a register-based follow-up study of 300,000 Finns. J Epidemiol Community Health (2008) 0.96
The impact of a large reduction in the price of alcohol on area differences in interpersonal violence: a natural experiment based on aggregate data. J Epidemiol Community Health (2008) 0.96
Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study. Eur Urol (2005) 0.95
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate (2001) 0.95
Inequalities in health. Policies to reduce income inequalities are unlikely to eradicate inequalities in mortality. BMJ (1999) 0.95
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate (2001) 0.93
Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol (2001) 0.92
Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology (2001) 0.92
Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol Rep (2000) 0.92
Educational inequalities in tuberculosis mortality in sixteen European populations. Int J Tuberc Lung Dis (2011) 0.91
Associations of SF-36 mental health functioning and work and family related factors with intentions to retire early among employees. Occup Environ Med (2006) 0.90
Economic difficulties and common mental disorders among Finnish and British white-collar employees: the contribution of social and behavioural factors. J Epidemiol Community Health (2009) 0.90
The relationship between employment grade and plasma fibrinogen level among Japanese male employees. YKKJ Research Group. Atherosclerosis (2000) 0.89
Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients. Prostate (2000) 0.89
Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer (2007) 0.89
The Finnish trial of prostate cancer screening: where are we now? BJU Int (2003) 0.88
Gender differences in the association of age with physical workload and functioning. Occup Environ Med (2005) 0.88
Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells. Inflamm Res (2005) 0.87
Effect of estrogen withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. Urology (1998) 0.86
Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. Int J Cancer (2000) 0.86
Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene (2008) 0.86
[Guidelines for German urologists on diagnosis of benign prostate syndrome]. Urologe A (2003) 0.85
Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. Cancer Res (1990) 0.85
Kinetic and morphometric responses of heterogeneous populations of experimental breast cancer cells in vivo. Cancer Res (1988) 0.85
Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. Int J Clin Pract (2011) 0.84
Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention. Prostate Cancer Prostatic Dis (2005) 0.83
[Guidelines of German urologists on therapy of benign prostate syndrome]. Urologe A (2003) 0.83
Programmed cell death as a new target for prostatic cancer therapy. Cancer Surv (1991) 0.83
Malignant nerve sheath tumors of the head and neck: four case studies and review of the literature. Eur Arch Otorhinolaryngol (1993) 0.83
Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol (1996) 0.83
Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol (1993) 0.81
Future concepts in the medical therapy of benign prostatic hyperplasia. Curr Opin Urol (2001) 0.81
Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma. Anticancer Res (1999) 0.81
Range of phytoplasma concentrations in various plant hosts as determined by competitive polymerase chain reaction. Phytopathology (2000) 0.81
Biological basis for chemohormonal therapy for prostatic cancer. Cancer Treat Res (1989) 0.81
Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy. Surgery (1995) 0.80
Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate (1987) 0.80
Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. J Surg Res (1995) 0.79
Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology (1994) 0.79
Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate (1994) 0.79
Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. Cancer Chemother Pharmacol (1989) 0.79